Vor Biopharma Stock Performance
| VOR Stock | USD 12.78 0.29 2.22% |
On a scale of 0 to 100, Vor Biopharma holds a performance score of 6. The entity has a beta of -0.37, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Vor Biopharma are expected to decrease at a much lower rate. During the bear market, Vor Biopharma is likely to outperform the market. Please check Vor Biopharma's maximum drawdown and rate of daily change , to make a quick decision on whether Vor Biopharma's existing price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vor Biopharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Vor Biopharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.22) | Five Day Return 3.82 | Year To Date Return 9.79 | Ten Year Return (98.30) | All Time Return (98.30) |
Last Split Factor 1:20 | Last Split Date 2025-09-19 |
1 | What technical signals suggest for Vor Biopharma Inc. stock - Weekly Profit Summary Risk Managed Investment Strategies - newser.com | 11/18/2025 |
2 | Disposition of 4164831 shares by Kress Jean-paul of Vor Biopharma at 17.8 subject to Rule 16b-3 | 12/05/2025 |
3 | Vor Biopharmas Surge New Opportunities - StocksToTrade | 12/16/2025 |
4 | Insider Trading | 12/18/2025 |
5 | VOR JP Morgan Lowers Price Target While Maintaining Overweight Rating VOR Stock News - GuruFocus | 12/19/2025 |
6 | Vor Biopharma Inc. Sees Large Growth in Short Interest - MarketBeat | 12/24/2025 |
7 | Gap Down Is Vor Biopharma Inc stock positioned well for digital economy - July 2025 Fed Impact AI Powered BuySell Recommendations - moha.gov.vn | 12/29/2025 |
8 | Vor Biopharma to Highlight Telitacicept at JPM Conference - TipRanks | 01/12/2026 |
9 | TUMI STELLT DIE NCHSTE GENERATION DER TUMI ALPHA KOLLEKTION MIT KAMPAGNEN MIT LANDO NORRIS UND WEI DAXUN VOR | 01/22/2026 |
10 | Disposition of 111041 shares by Ra Capital Management, L.p. of Vor Biopharma at 29.32 subject to Rule 16b-3 | 02/04/2026 |
11 | Vor Biopharma Stock Price Down 4 percent - Whats Next - MarketBeat | 02/12/2026 |
| Begin Period Cash Flow | 33.8 M | |
| Total Cashflows From Investing Activities | 96.9 M |
Vor Biopharma Relative Risk vs. Return Landscape
If you would invest 1,002 in Vor Biopharma on November 16, 2025 and sell it today you would earn a total of 276.00 from holding Vor Biopharma or generate 27.54% return on investment over 90 days. Vor Biopharma is generating 0.7448% of daily returns assuming volatility of 8.5471% on return distribution over 90 days investment horizon. In other words, 76% of stocks are less volatile than Vor, and above 85% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vor Biopharma Target Price Odds to finish over Current Price
The tendency of Vor Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 12.78 | 90 days | 12.78 | about 42.26 |
Based on a normal probability distribution, the odds of Vor Biopharma to move above the current price in 90 days from now is about 42.26 (This Vor Biopharma probability density function shows the probability of Vor Stock to fall within a particular range of prices over 90 days) .
Vor Biopharma Price Density |
| Price |
Predictive Modules for Vor Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vor Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vor Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vor Biopharma is not an exception. The market had few large corrections towards the Vor Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vor Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vor Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | -0.37 | |
σ | Overall volatility | 2.87 | |
Ir | Information ratio | -0.0073 |
Vor Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vor Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vor Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vor Biopharma is way too risky over 90 days horizon | |
| Vor Biopharma appears to be risky and price may revert if volatility continues | |
| Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (99.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97. | |
| Vor Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Vor Biopharma Stock Price Down 4 percent - Whats Next - MarketBeat |
Vor Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vor Stock often depends not only on the future outlook of the current and potential Vor Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vor Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.4 M | |
| Cash And Short Term Investments | 91.9 M |
Vor Biopharma Fundamentals Growth
Vor Stock prices reflect investors' perceptions of the future prospects and financial health of Vor Biopharma, and Vor Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vor Stock performance.
| Return On Equity | -1.25 | ||||
| Return On Asset | -1.44 | ||||
| Current Valuation | 376.09 M | ||||
| Shares Outstanding | 41.52 M | ||||
| Price To Book | 3.14 X | ||||
| EBITDA | (117.66 M) | ||||
| Net Income | (116.91 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 31.83 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | (246.54) X | ||||
| Cash Flow From Operations | (99.66 M) | ||||
| Earnings Per Share | (386.86) X | ||||
| Market Capitalization | 542.66 M | ||||
| Total Asset | 142.89 M | ||||
| Retained Earnings | (456.99 M) | ||||
| Working Capital | 77.89 M | ||||
About Vor Biopharma Performance
Assessing Vor Biopharma's fundamental ratios provides investors with valuable insights into Vor Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vor Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.74) | (0.77) | |
| Return On Capital Employed | (1.12) | (1.18) | |
| Return On Assets | (0.74) | (0.77) | |
| Return On Equity | (1.39) | (1.32) |
Things to note about Vor Biopharma performance evaluation
Checking the ongoing alerts about Vor Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vor Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vor Biopharma is way too risky over 90 days horizon | |
| Vor Biopharma appears to be risky and price may revert if volatility continues | |
| Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (99.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97. | |
| Vor Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Vor Biopharma Stock Price Down 4 percent - Whats Next - MarketBeat |
- Analyzing Vor Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vor Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Vor Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vor Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vor Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vor Biopharma's stock. These opinions can provide insight into Vor Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.